Business Wire (Mon, 10-Aug 4:30 PM ET)
Business Wire (Tue, 4-Aug 4:30 PM ET)
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 17-Jul 4:30 PM ET)
Business Wire (Tue, 23-Jun 8:30 AM ET)
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Business Wire (Tue, 16-Jun 8:30 AM ET)
DiaMedica’s Strong Cash Position and Clinical Progress Signal a Focused Path Forward
Market Chameleon (Tue, 31-Mar 5:21 AM ET)
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Diamedica Therapeutics trades on the NASDAQ stock market under the symbol DMAC.
As of September 1, 2026, DMAC stock price climbed to $6.45 with 145,728 million shares trading.
DMAC has a beta of 1.00, meaning it tends to be less sensitive to market movements. DMAC has a correlation of 0.05 to the broad based SPY ETF.
DMAC has a market cap of $347.55 million. This is considered a Small Cap stock.
In the last 3 years, DMAC traded as high as $10.42 and as low as $1.94.
The top ETF exchange traded funds that DMAC belongs to (by Net Assets): IWM, VXF, IWO, VTWO, IWC.
DMAC has underperformed the market in the last year with a price return of +13.0% while the SPY ETF gained +19.3%. However, in the short term, DMAC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.7% vs +1.0% return in SPY. But in the last 2 weeks, DMAC shares have been beat by the market, returning -2.6% compared to an SPY return of -1.4%.
DMAC support price is $6.15 and resistance is $6.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMAC shares will trade within this expected range on the day.
